Diana Dowd, center, talks with her friend, Lauri Roskamp, right, during an appointment at OHSU, Jan. 8, 2020. Dowd took part in a clinical trial treating a rare stomach cancer, GIST, which was recently approved by the FDA. The scans show a comparison of Dowd's stomach tumors after, left, and before her treatment. (OHSU/Kristyna Wentz-Graff) EDITOR'S NOTE: PERSONAL INFORMATION HAS BEEN REMOVED FROM THE XRAYS. NO OTHER CONTENT HAS BEEN MODIFIED.

Michael Heinrich, M.D., left, talks with Diana Dowd, center and her friend Lauri Roskamp, during an appointment at OHSU, Jan. 8, 2020. Dowd took part in a clinical trial treating a rare stomach cancer, GIST, which was recently approved by the FDA. (OHSU/Kristyna Wentz-Graff)

Diana Dowd, center, has an appointment with Michael Heinrich, M.D., at OHSU, Jan. 8, 2020. Dowd took part in a clinical trial for a drug treating a rare stomach cancer, GIST. The drug that recently approved by the FDA. (OHSU/Kristyna Wentz-Graff)

Michael Heinrich, M.D., at OHSU, Jan. 8, 2020, wears a "Slay GIST" hat during an appointment with a patient. Heinrich consulted with the company that developed a drug treating a rare stomach cancer, GIST. The drug was recently approved by the FDA. (OHSU/Kristyna Wentz-Graff)

Jackilen Shannon, Ph.D., R.D., co-director of the OHSU Knight Cancer Institute Community Partnership Program.
(OHSU)